Dissecting non-small cell lung cancer (NSCLC) with blood proteomics-from surgical to immunotherapeutic responses
Blood proteins predict lung cancer recurrence after surgery and immunotherapy response, supporting protein monitoring alongside tissue testing.
Dual-platform plasma proteomics (SomaScan + NULISA) of 56 NSCLC patients at multiple surgical and ICI timepoints identified distinct plasma protein signatures predicting surgical recurrence (elevated COX7A2L, FGF19, lower MUC16, IL36G) and ICI response (lower baseline IL-6, CCL19, SPP1), with key biomarkers validated across platforms. This study supports blood-based proteomic monitoring as a complement to tissue biopsy for NSCLC management decisions.
What the study was
- Study design
- Prospective biomarker discovery study (plasma proteomics)
- Population
- NSCLC patients at Princess Alexandra Hospital (n=56, 87 timepoints pre/post-surgery and pre/post-ICI)
- Sample size
- 56
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- NPJ Precision Oncology
Why it surfaced
Multi-timepoint prospective proteomics with independent cross-platform validation in NSCLC. NPJ Precision Oncology. Dual-platform approach (7596 + 250 proteins) is technically rigorous. Clinical validation in larger cohorts needed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.